A single center study of cancer patients with chronic kidney disease

Abu-Sayeef Mirza, Sarah Mushtaq, Revati Reddy, Mina Mousa, Kullatham Kongpakpaisarn, Chandrashekar Bohra, Sean Verma, Rahul Mhaskar, Rachid Baz, Claude Bassil


Purpose: It is clinically understood that chronic kidney disease (CKD) and cancer are interrelated. Yet, few studies measure how renal outcomes vary according to common malignancies and common therapeutic agents. We report the incidence and the nature of CKD among cancer patients from a single institution.

Methods: A retrospective chart review of cancer patients managed in the onconephrology clinic at the Moffitt Cancer Center from 05/01/2015 to 07/31/2016 was conducted. Patients with kidney injury were included in this study. Renal function was recorded at three-month follow-up intervals for 15-month duration.

Results: Out of the total 88 patients with median age of 68 years, 63 patients (~ 72%) were diagnosed with chronic kidney disease (CKD), whereas the remaining had acute kidney injury. Kidney cancer and multiple myeloma represented the single malignancies with the largest proportion of CKD with 12 patients each (~14% each). Patients with kidney cancer had a mean creatinine of (2.35, 1.74 SD) mg/dl compared to patients without kidney cancer with creatinine (1.97, 1.07 SD) mg/dl. Abdominal cancers represented the highest frequency category of malignancies in this sample (n = 38), and about 32 (84%) of these patients had CKD. About 80% of patients with genitourinary cancers (n = 27) had CKD. In terms of prescribed chemotherapeutic agents, patients treated with tyrosine kinase inhibitors had a lower average estimated glomerular filtration rate (28.37, 9.86 SD) mL/min/1.73 m2 compared to other chemotherapeutic agents, though this was weakly significant (p-value = 0.07). Similar renal outcomes per malignancy and chemotherapy are reported.

Conclusion: This group of patients demonstrated the frequency of chronic kidney disease differs depending on the type of malignancy or chemotherapy. A multidisciplinary approach involving oncologists and nephrologists should be adopted to prevent further renal damage from cancer and its therapies.


oncology, chemotherapy, chronic kidney disease, epidemiology


Izzedine H, Perazella MA. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant. 2015;30(12):1979-88.

Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010;23(3):253-62.

Shiao CC, Wu PC, Huang TM, et al. Long-term remote organ consequences following acute kidney injury. Crit care. 2015;19:438.

Yang Y, Li H-y, Zhou Q, et al. Renal function and all-cause mortality risk among cancer patients. Medicine. 2016;95(20):e3728.

Airy M, Raghavan R, Truong LD, et al. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant. 2013;28(10):2502-9.

Mieczkowski M, Matuszkiewicz-Rowinska J, Koscielska M. Anti-cancer agents nephrotoxicity. Wiadomosci lekarskie. 2015;68(4 Pt 2):650-4.

A Troxell ML, Higgins JP, Kambham N. Renal pathology associated with hematopoietic stem cell transplantation. Adv anat pathol. 2014;21(5):330-40.

Andrassy KM. Comments on 'KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease'. Kidney Int. 2013 Sep;84(3):622-3.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.

Levey ASGTK, JW. A Simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:0828.

Stevens LA, Coresh J, Feldman Hi, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749-57.

KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. American Journal of Kidney Disease. 2002.

Davison AM. Renal Diseases associated with malignancies. In. Nephrology Dialysis Transplantation. 2001:13-4.

Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007;298(17):2038-47.

Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84.

Cosmai LP, Camillo, Maurizio G. Chapter 13: CKD as a Complication of Cancer. In: Onco-Nephrology Curriculum. Am Soc Nephrol. 2016.

Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br j cancer. 2010;103(12):1815-21.

Konigsbrugge O, Lotsch F, Zielinski C, et al. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb res. 2014;134(1):44-9.

Chalisey A, Karim M. Mass Effect from Hepatomegaly in Polycystic Kidney Disease. J Gen Intern Med. 2014;29(12):1713.

Friedlander JI, Duty BD, Okeke Z, et al. Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies. J endourol. 2012;26(2):102-9.

Finkel KW, Foringer JR. Renal disease in patients with cancer. Nat clin prac Nephrol. 2007;3(12):669-78.

Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33-64.

Naughton CA. Drug-induced nephrotoxicity. American family physician. 2008;78(6):743-50.

Schetz M, Dasta J, Goldstein S, et al. Drug-induced acute kidney injury. Current opinion in critical care. 2005;11(6):555-65.

Bhat ZY, Cadnapaphornchai P, Ginsburg K, et al. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: An observational cohort study. PLoS ONE. 2015;10(11):e0142225.

Peres LA, da Cunha AD, Jr. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras de Nefrol. 2013;35(4):332-40.

Yilmaz M, Lahoti A, O'Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121(21):3894-904.

Nakagawa T, Sasahara M, Haneda M, et al. Role of PDGF B-Chain and PDGF receptors in Rat tubular regeneration after acute injury. Am J Pathol. 1999;155(5):1689-99.

Hinson JS, Ehmann MR, Fine DM, et al. Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med. 2017;69(5):577-86.e4

Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Jama. 2003;289(9):1107-16.

DOI: http://dx.doi.org/10.14319/ijcto.61.1

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013